BetterLife Pharma (BETR) AI Stock Analysis

• Market Cap: C$7.59M
• Dividend Yield: N/A
• Average Volume (3M): 121.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.10
• Revenue Growth: N/A
• EPS Growth: 85.61%
• Country: CA
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 151,838,730
• 10 Day Avg. Volume: 118,740
• 30 Day Avg. Volume: 121,961
• PEG Ratio: -0.60
• Price to Book (P/B): -1.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 21 Underperform
• Price Target: ―

BetterLife Pharma is currently in a precarious financial position with no revenue, substantial losses, and a high leverage risk due to negative equity. Technical indicators show a lack of momentum, and the valuation is unattractive due to negative earnings. The overall outlook is negative, reflecting significant financial instability.

BetterLife Pharma Business Overview & Revenue Model

Company Description

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's pipeline products include BETR-001 for the treatment of major depressive disorder, treatment resistance depression, cluster headaches, and post-traumatic stress disorder; and BETR-002 to treat benzodiazepine dependency, anxiety, and spasticity. It is also developing MM-003 for treatment of COVID-19 and other respiratory viral infections; MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and AP-002 for the treatment of cancer. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

How the Company Makes Money

BetterLife Pharma makes money primarily through the development and commercialization of its therapeutic products. The company's revenue model is based on the successful advancement of its drug candidates through clinical trials and obtaining regulatory approvals, which can lead to partnerships or licensing agreements with larger pharmaceutical companies. Additionally, as these therapies reach the market, BetterLife Pharma could generate revenue through direct sales or royalties from licensing agreements. Investment from venture capital or strategic partners also plays a significant role in funding the company's research and development activities, which indirectly contributes to its financial sustainability.

BetterLife Pharma Financial Statement Overview

Summary

BetterLife Pharma is facing severe financial challenges with no revenue generation, substantial losses, negative equity, and unsustainable cash flows. The company's financial health is weak, with high leverage and dependency on financing activities to maintain liquidity.

Income Statement

BetterLife Pharma has not generated any revenue over the past years, leading to negative gross profit and net income. The company shows significant losses, with high negative EBIT and EBITDA margins. The absence of revenue growth and persistent losses highlight financial challenges.

Balance Sheet

The company has negative stockholders' equity, indicating liabilities exceed assets, which is a significant financial concern. The debt-to-equity ratio cannot be computed due to negative equity, but substantial debt levels pose a high leverage risk. The financial structure is unstable, with liabilities consistently rising.

Cash Flow

Operating cash flows are negative, reflecting cash outflows from operations. Free cash flow is also negative, indicating financial strain in sustaining operations. The financing activities seem to be the primary source of liquidity, but the overall cash flow position is unsustainable.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	-18.44K	-18.43K	―
EBITDA	49.17K	0.00	-3.19M	-11.92M	-9.24M	-7.61M
Net Income	-839.95K	-3.52M	-2.89M	-12.16M	-9.02M	-36.35M
Balance Sheet
Total Assets	229.34K	224.96K	324.75K	1.16M	74.73K	1.34M
Cash, Cash Equivalents and Short-Term Investments	22.16K	8.18K	37.38K	173.51K	8.31K	154.72K
Total Debt	643.35K	1.30M	1.47M	1.40M	1.19M	500.00K
Total Liabilities	6.04M	7.59M	8.02M	5.04M	7.61M	5.95M
Stockholders Equity	-9.12M	-10.68M	-10.81M	-3.88M	-10.73M	-4.61M
Cash Flow
Free Cash Flow	-347.77K	-2.02M	-2.47M	-11.20M	-1.50M	-7.26M
Operating Cash Flow	-347.77K	-2.02M	-2.47M	-11.20M	-1.50M	-7.16M
Investing Cash Flow	0.00	0.00	0.00	―	165.04K	-71.55K
Financing Cash Flow	243.10K	1.99M	2.50M	11.23M	1.34M	4.09M

BetterLife Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BETR, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.32 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BETR.

BetterLife Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	47 Neutral	C$13.79M	-1.70	―	―	-3.93%	-575.24%
HEM	41 Neutral	C$16.02M	-2.92	―	―	―	-24.89%
KNE	41 Neutral	C$5.86M	-2.87	―	―	―	―
BETR	21 Underperform	C$7.59M	-3.76	―	―	―	85.61%

BetterLife Pharma Corporate Events

BetterLife Pharma Secures Patent for BETR-001, Boosting Market Position

BetterLife Pharma announced that the USPTO granted a composition of matter patent for BETR-001, a non-hallucinogenic LSD derivative with significant commercial potential. This patent strengthens BetterLife’s intellectual property position, ensuring protection and viability for BETR-001 in treating various mental health disorders.

BetterLife Pharma Achieves Key Cardiac Safety Milestone

BetterLife Pharma has announced promising cardiac safety data for its LSD derivative, BETR-001, which shows minimal impact on crucial cardiac ion channels. This positive outcome positions the company closer to initiating clinical trials, advancing its efforts in developing treatments for neuro-psychiatric and neurological disorders.

BetterLife Pharma Advances with Genotoxicity Data

BetterLife Pharma has reported promising safety data for its lead drug candidate BETR-001, a non-hallucinogenic LSD derivative, showing no genotoxic effects. This positive outcome brings the company closer to starting clinical trials for this innovative treatment aimed at neuro-psychiatric and neurological disorders. Additionally, BetterLife has issued common shares and warrants through the conversion of its convertible debentures.